ADIAL PHARMACEUTICALS, INC.
A clinical-stage biopharma developing genetically targeted therapies for addiction.
ADIL | US
Overview
Corporate Details
- ISIN(s):
- US00688A1060
- LEI:
- Country:
- United States of America
- Address:
- 1180 SEMINOLE TRAIL, 22901 CHARLOTTESVILLE
- Website:
- https://www.adialpharma.com/
- Sector:
- Manufacturing
Description
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The company's lead investigational drug candidate is AD04, a genetically targeted, serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder (AUD). AD04 is being developed in conjunction with a proprietary companion diagnostic genetic test. This test is designed to identify patients with specific genotypes who are most likely to respond to the treatment, representing a personalized medicine approach to managing addiction.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ADIAL PHARMACEUTICALS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ADIAL PHARMACEUTICALS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ADIAL PHARMACEUTICALS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
